期刊
SEMINARS IN HEMATOLOGY
卷 47, 期 2, 页码 107-114出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1053/j.seminhematol.2010.01.001
关键词
-
类别
资金
- Leukaemia Research
- Cancer Research UK
- Association for International Cancer Research
- Medical Research Council
The last decade has seen the monoclonal antibody (mAb), rituximab, transform clinical management of many non-Hodgkin lymphomas and more recently provide new opportunities for controlling autoimmune conditions, such as rheumatoid arthritis. Although not yet fully determined, the explanation for this success appears to lie with the inherent properties of its target, CD20, which allow rituximab to recruit potent cytotoxic effectors with unusual efficiency. In this review we detail the properties of CD20 that make it such an effective therapeutic target and describe how different mAbs change the membrane distribution and internalization of CD20 and have distinct modes of cytotoxic activity. Semin Hematol 47:107-114. (C) 2010 Published by Elsevier Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据